FDA
-
-
-
-
-
-
-
Lineage (LCTX) Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
-
-
-
-
-
-
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
-
-
-
-
-
-
-
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
-
-
-
-
-
-
-
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
-
-
-
-
-
-
-
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

